Schleicher E D, Weigert C
Department of Internal Medicine, University of Tübingen, Germany.
Kidney Int Suppl. 2000 Sep;77:S13-8. doi: 10.1046/j.1523-1755.2000.07703.x.
The hexosamine biosynthetic pathway has been hypothesized to be involved in the development of insulin resistance and diabetic vascular complications. In particular, it was demonstrated that hyperglycemia-induced production of transforming growth factor-beta (TGF-beta1), a prosclerotic cytokine causally involved in the development of diabetic nephropathy. Several lines of evidence indicate that TGF-beta1 induction is mediated by the hexosamine pathway. In cultured mesangial cells, high glucose levels induce TGF-beta1 production. This effect is eliminated by inhibition of glutamine: fructose-6-phosphate-amidotransferase (GFAT), the rate-limiting enzyme of this pathway. Furthermore, stable overexpression of GFAT increased levels of TGF-beta1 protein, mRNA, and promoter activity. Inasmuch as stimulation or inhibition of GFAT increased or decreased high glucose-stimulated activity of protein kinase C (PKC), respectively, the observed effects appear to be transduced by PKC. In similar experiments, involvement of the hexosamine pathway in hyperglycemia-induced production of cytokines (TGF-alpha and basic fibroblast growth factor [bFGF]) was demonstrated in vascular smooth muscle cells. These studies also revealed a rapid increase in GFAT activity by treatment with agents that elevated levels of cyclic adenosine 3',5' monophosphate (cAMP), thus indicating that GFAT activity is tightly regulated by cAMP-dependent phosphorylation. Using immunohistochemistry and in situ hybridization, high expression of GFAT was found in human adipocytes, skeletal muscle, vascular smooth muscle cells, and renal tubular epithelial cells. whereas glomerular cells remained essentially unstained. However, significant staining occurred in glomerular cells of patients with diabetic nephropathy. Current data indicate that the flux through the hexosamine pathway, regulated by GFAT, may be causally involved in the development of diabetic vascular disease, particularly diabetic nephropathy.
己糖胺生物合成途径被推测与胰岛素抵抗及糖尿病血管并发症的发生发展有关。具体而言,研究表明高血糖诱导转化生长因子-β(TGF-β1)的产生,这是一种与糖尿病肾病发生有因果关系的促硬化细胞因子。多项证据表明,TGF-β1的诱导是由己糖胺途径介导的。在培养的系膜细胞中,高糖水平会诱导TGF-β1的产生。该效应可通过抑制谷氨酰胺:果糖-6-磷酸酰胺转移酶(GFAT)来消除,GFAT是此途径的限速酶。此外,GFAT的稳定过表达增加了TGF-β1蛋白、mRNA及启动子活性的水平。由于刺激或抑制GFAT分别增加或降低了蛋白激酶C(PKC)的高糖刺激活性,因此观察到的效应似乎是由PKC转导的。在类似实验中,己糖胺途径参与血管平滑肌细胞中高血糖诱导的细胞因子(TGF-α和碱性成纤维细胞生长因子[bFGF])产生得到了证实。这些研究还揭示,用能提高环磷酸腺苷(cAMP)水平的试剂处理后,GFAT活性会迅速增加,这表明GFAT活性受cAMP依赖性磷酸化的严格调控。通过免疫组织化学和原位杂交发现,GFAT在人脂肪细胞、骨骼肌、血管平滑肌细胞和肾小管上皮细胞中高表达,而肾小球细胞基本未染色。然而,糖尿病肾病患者的肾小球细胞出现了明显染色。目前的数据表明,由GFAT调节的己糖胺途径通量可能与糖尿病血管疾病,尤其是糖尿病肾病的发生有因果关系。